




RealRate

PHARMACEUTICAL 2022

Karyopharm Therapeutics Inc. Rank 401 of 466





RealRate

PHARMACEUTICAL 2022

Karyopharm Therapeutics Inc. Rank 401 of 466



The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 159% points.

The company's Economic Capital Ratio, given in the ranking table, is -76%, being 154% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	275,606
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	73,718
Liabilities, Non-Current	8,969
Other Assets	28,057
Other Compr. Net Income	-327
Other Expenses	3,670
Other Liabilities	302,291
Other Net Income	-25,549
Other Revenues	209,819
Property and Equipment	1,642
Research and Development	160,842
Selling, General and Administrative Expense	143,846

Output Variable	Value in 1000 USD
Assets	305,305
Liabilities	384,978
Expenses	308,358
Revenues	209,819
Stockholders Equity	-79,673
Net Income	-124,088
Comprehensive Net Income	-124,252
Economic Capital Ratio	-76%